TN2016000546A1 - Aminoester derivatives - Google Patents

Aminoester derivatives

Info

Publication number
TN2016000546A1
TN2016000546A1 TN2016000546A TN2016000546A TN2016000546A1 TN 2016000546 A1 TN2016000546 A1 TN 2016000546A1 TN 2016000546 A TN2016000546 A TN 2016000546A TN 2016000546 A TN2016000546 A TN 2016000546A TN 2016000546 A1 TN2016000546 A1 TN 2016000546A1
Authority
TN
Tunisia
Prior art keywords
sub
sup
buffer
edta
hci
Prior art date
Application number
TN2016000546A
Other languages
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Charles Baker-Glenn
Wesley Blackaby
Carmelida Capaldi
Ian Linney
Naimisha Trivedi
De Pöel Hervé Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of TN2016000546A1 publication Critical patent/TN2016000546A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
TN2016000546A 2014-06-05 2015-06-03 Aminoester derivatives TN2016000546A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171266 2014-06-05
PCT/EP2015/062417 WO2015185649A1 (en) 2014-06-05 2015-06-03 Aminoester derivatives

Publications (1)

Publication Number Publication Date
TN2016000546A1 true TN2016000546A1 (en) 2018-04-04

Family

ID=50884281

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000546A TN2016000546A1 (en) 2014-06-05 2015-06-03 Aminoester derivatives

Country Status (32)

Country Link
US (2) US9763924B2 (enExample)
EP (1) EP3152201B1 (enExample)
JP (1) JP2017516824A (enExample)
KR (1) KR102420323B1 (enExample)
CN (1) CN106459020B (enExample)
AR (1) AR100732A1 (enExample)
AU (1) AU2015270539B2 (enExample)
BR (1) BR112016026725B1 (enExample)
CA (1) CA2953198C (enExample)
CL (1) CL2016003117A1 (enExample)
CY (1) CY1120698T1 (enExample)
DK (1) DK3152201T3 (enExample)
EA (1) EA032761B1 (enExample)
ES (1) ES2688826T3 (enExample)
GE (1) GEP20186922B (enExample)
HR (1) HRP20181967T1 (enExample)
HU (1) HUE042119T2 (enExample)
IL (1) IL249325B (enExample)
LT (1) LT3152201T (enExample)
MA (1) MA39947B1 (enExample)
MX (1) MX377669B (enExample)
PE (1) PE20161557A1 (enExample)
PH (1) PH12016502221A1 (enExample)
PL (1) PL3152201T3 (enExample)
PT (1) PT3152201T (enExample)
RS (1) RS57787B1 (enExample)
SG (1) SG11201610132RA (enExample)
SI (1) SI3152201T1 (enExample)
TN (1) TN2016000546A1 (enExample)
TW (1) TW201625600A (enExample)
WO (1) WO2015185649A1 (enExample)
ZA (1) ZA201608331B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42048A (fr) 2015-05-07 2018-03-14 Chiesi Farm Spa Dérivés d'aminoesters
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
AR104829A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivados de aminoésteres
CN106866474B (zh) * 2017-02-16 2018-12-28 陕西师范大学 一种手性α-芳基甘氨酸酯衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EP2928879B1 (en) * 2012-12-05 2018-02-28 Chiesi Farmaceutici S.p.A. Phenylethylpyridine derivatives as pde4-inhibitors and muscarinic receptor antagonists
CN104822671B (zh) 2012-12-05 2017-10-31 奇斯药制品公司 作为pde4抑制剂的苯乙基吡啶衍生物
HK1212986A1 (zh) 2012-12-05 2016-06-24 奇斯药制品公司 作为pde4-抑制剂的苯基乙基吡啶衍生物
CA2932486A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
WO2015082616A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Heteroaryl derivatives for the treatment of respiratory diseases

Also Published As

Publication number Publication date
EP3152201B1 (en) 2018-08-29
ES2688826T3 (es) 2018-11-07
ZA201608331B (en) 2018-05-30
AU2015270539A1 (en) 2016-12-22
LT3152201T (lt) 2018-10-10
PL3152201T3 (pl) 2019-02-28
CA2953198A1 (en) 2015-12-10
BR112016026725B1 (pt) 2024-02-27
US10117860B2 (en) 2018-11-06
MX377669B (es) 2025-03-11
DK3152201T3 (en) 2018-11-19
SI3152201T1 (sl) 2018-10-30
EP3152201A1 (en) 2017-04-12
IL249325B (en) 2018-12-31
CA2953198C (en) 2023-06-13
KR20170015294A (ko) 2017-02-08
WO2015185649A9 (en) 2017-01-05
AU2015270539B2 (en) 2018-11-08
JP2017516824A (ja) 2017-06-22
CN106459020B (zh) 2019-06-18
TW201625600A (zh) 2016-07-16
CY1120698T1 (el) 2019-12-11
PE20161557A1 (es) 2017-02-07
HRP20181967T1 (hr) 2019-02-08
IL249325A0 (en) 2017-02-28
MA39947A (fr) 2017-04-12
AR100732A1 (es) 2016-10-26
KR102420323B1 (ko) 2022-07-13
SG11201610132RA (en) 2017-01-27
CL2016003117A1 (es) 2017-06-23
BR112016026725A8 (pt) 2021-06-29
PT3152201T (pt) 2018-10-26
CN106459020A (zh) 2017-02-22
MX2016015958A (es) 2017-04-10
PH12016502221A1 (en) 2017-02-06
RS57787B1 (sr) 2018-12-31
US20150352091A1 (en) 2015-12-10
HUE042119T2 (hu) 2019-06-28
BR112016026725A2 (pt) 2017-08-15
EA032761B1 (ru) 2019-07-31
US20170340616A1 (en) 2017-11-30
US9763924B2 (en) 2017-09-19
MA39947B1 (fr) 2018-10-31
GEP20186922B (en) 2018-11-12
WO2015185649A1 (en) 2015-12-10
EA201692227A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
PH12016502221A1 (en) Aminoester derivatives
Koehler et al. Expanding the utility of NMR restraints with paramagnetic compounds: background and practical aspects
Farley et al. Identification and quantification of protein posttranslational modifications
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
CA2868907C (en) Anti-hla-b*27 antibodies and uses thereof
HK1256737A1 (zh) 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
WO2011056975A3 (en) Genetically encoded calcium indicators and methods of use
MY182355A (en) Hmo synthesis
Thorsheim et al. Chemistry of xylopyranosides
GB2468006A (en) Screening
WO2010039802A3 (en) Methods and compositions for isolating nucleic acid
TW200626604A (en) Methods of preparing pimecrolimus
WO2011077099A3 (en) Methods for the purification of cucurbituril
WO2009033163A3 (en) Borrelia diagnostics and screening methods
MX2011009025A (es) Sistema de vector de expresion que comprende dos marcadores de seleccion.
WO2010114239A3 (ko) 도로의 면형 데이터를 이용한 맵 매칭장치 및 그 방법
GB201017978D0 (en) Multiplex amplification and detection
Sołtysik et al. ERα36–another piece of the estrogen puzzle
MX2015007590A (es) Auxiliares de filtro de tierra diatomacea que contienen un bajo contenido de silice cristalina.
WO2010128518A3 (en) Novel process for the preparation of cisatracurium besylate
Jean-Charles et al. Chapter nine-cellular roles of beta-arrestins as substrates and adaptors of ubiquitination and deubiquitination
WO2011143575A3 (en) smFRET WITH MEMBRANE PROTEINS
WO2012168344A8 (en) BINDING COMPOUNDS TO HUMAN β1-ADRENORECEPTOR (β1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-βA1-AR ANTIBODIES
Campbell et al. Homobivalent conjugation increases the allosteric effect of 9-aminoacridine at the α1-adrenergic receptors
WO2013169931A3 (en) Assays and cell-based tests using a receptor na/k-atpase/src complex and uses thereof